Examining the correlation between treatment effects in clinical trials and economic modeling.

Clinical trial correlation between treatment effects depression economic modeling independence

Journal

Expert review of pharmacoeconomics & outcomes research
ISSN: 1744-8379
Titre abrégé: Expert Rev Pharmacoecon Outcomes Res
Pays: England
ID NLM: 101132257

Informations de publication

Date de publication:
Oct 2022
Historique:
pubmed: 19 5 2022
medline: 6 10 2022
entrez: 18 5 2022
Statut: ppublish

Résumé

Many diseases have a sequential treatment pathway. Compared with patients without previous treatment, patients who fail initial treatment may have lower success rates with a second treatment. This phenomenon can be explained by a correlation between treatment effects. We developed a statistical model of covariance for the underlying unobserved correlation between treatments and established a mathematical expression for the magnitude of the latent correlation term. We conducted a simulation study of clinical trials to investigate the correlation between two treatments and explored clinical examples based on published literature to illustrate the identification and evaluation of these correlations. Our simulation study confirmed that a treatment correlation reduces the probability of success for the second treatment, compared with no correlation. We found that treatment correlations may be observable in clinical trials, such as for depression and lung cancer, and the magnitude of correlation may be estimated. We illustrated that treatment correlations can be incorporated into an economic model, with possible impacts on cost-effectiveness results. Additional applications of correlation concepts are also discussed. We evaluated the correlation between treatment effects and our approach can be applied to clinical trial design and economic modeling of sequential clinical treatment pathways.

Identifiants

pubmed: 35582876
doi: 10.1080/14737167.2022.2079497
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1071-1078

Auteurs

Xuanqian Xie (X)

Health Technology Assessment Program, Ontario Health, Toronto, Ontario, Canada.

Myra Wang (M)

Health Technology Assessment Program, Ontario Health, Toronto, Ontario, Canada.

Olga Gajic-Veljanoski (O)

Health Technology Assessment Program, Ontario Health, Toronto, Ontario, Canada.

Chenglin Ye (C)

Department of Oncology Biostatistics, Genentech, South San Francisco, California, USA.

Daniel M Blumberger (DM)

Temerty Centre for Therapeutic Brain Intervention at the Centre for Addiction and Mental Health and Department of Psychiatry, University of Toronto, Ontario, Canada.

Andrei Volodin (A)

Sino-Canada Research Centre of Nonlinear Dynamics and Noise Control, Xiamen University of Technology and the University of Regina, Xiamen University of Technology, Xiamen, Fujian, People's Republic of China.
Department of Mathematics and Statistics, University of Regina, Regina, Saskatchewan, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH